Hematopoietic stem cell transplantation for acute lymphoblastic leukemia: why do adolescents and young adults outcomes differ from those of children? A retrospective study on behalf of the Francophone Society of Stem Cell Transplantation and Cellular Therapy (SFGM-TC).


Journal

Journal of cancer research and clinical oncology
ISSN: 1432-1335
Titre abrégé: J Cancer Res Clin Oncol
Pays: Germany
ID NLM: 7902060

Informations de publication

Date de publication:
Apr 2023
Historique:
received: 11 03 2022
accepted: 09 04 2022
pubmed: 5 5 2022
medline: 22 3 2023
entrez: 4 5 2022
Statut: ppublish

Résumé

In the acute lymphoblastic leukemia (ALL) landscape, adolescents and young adults (AYA) often present high-risk diseases and increased chemotherapy-related toxicity. Studies analyzing the outcomes of AYA after hematopoietic stem cell transplantation (HSCT) are scarce. Our study aimed to compare the outcomes of children and AYA with ALL after HSCT and to determine the factors influencing potential differences. 891 patients, from the SFGM-TC registry, aged between 1 and 25 years who received HSCT between 2005 and 2012 were included. The outcomes of AYA were compared to the ones of their younger counterparts. Five-year OS and GRFS were lower in AYA: 53.1% versus 64% and 36% versus 47% (p = 0.0012 and p = 0.007, respectively). WhileCIR was similar in both groups, 5 year-treatment related mortality was higher in AYA: 19% versus 13% (p = 0.04). The lower GRFS in AYA was mainly explained by a higher chronic graft versus host disease (cGvHD) incidence: 32% versus 19% (p < 0.001). Use of peripheral blood stem cells and use of anti-thymoglobulin appeared to be the main factors impacting cGvHD occurrence in AYA. AYA have worse outcomes than children after HSCT for ALL because of a greater risk of TRM due to cGvHD. HSCT practices should be questioned in this population.

Identifiants

pubmed: 35507103
doi: 10.1007/s00432-022-04021-1
pii: 10.1007/s00432-022-04021-1
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1473-1483

Informations de copyright

© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Références

Bleyer WA (2002) Cancer in older adolescents and young adults: epidemiology, diagnosis, treatment, survival, and importance of clinical trials. Med Pediatr Oncol 38:1–10
doi: 10.1002/mpo.1257 pubmed: 11835231
Boissel N, Baruchel A (2018) Acute lymphoblastic leukemia in adolescent and young adults: treat as adults or as children? Blood 132:351–361
doi: 10.1182/blood-2018-02-778530 pubmed: 29895662
Boissel N, Sender LS (2015) Best practices in adolescent and young adult patients with acute lymphoblastic leukemia: a focus on asparaginase. J Adolesc Young Adult Oncol 4:118–128
doi: 10.1089/jayao.2015.0014 pubmed: 26421220 pmcid: 4575545
Boissel N, Auclerc M-F, Lhéritier V, Perel Y, Thomas X, Leblanc T, Rousselot P, Cayuela J-M, Gabert J, Fegueux N et al (2003) Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol off J Am Soc Clin Oncol 21:774–780
doi: 10.1200/JCO.2003.02.053
Burke PW, Douer D (2014) Acute lymphoblastic leukemia in adolescents and young adults. Acta Haematol 132:264–273
doi: 10.1159/000360204 pubmed: 25228551
Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, MacMillan ML, Stefanski HS, Weisdorf DJ, Verneris MR (2013) Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 19:138–142
doi: 10.1016/j.bbmt.2012.08.020
Burke MJ, Gossai N, Cao Q, Macmillan ML, Warlick E, Verneris MR (2014) Similar outcomes between adolescent/young adults and children with AML following allogeneic hematopoietic cell transplantation. Bone Marrow Transplant 49:174–178
doi: 10.1038/bmt.2013.171 pubmed: 24185590
Campregher PV, Hamerschlak N, Colturato VAR, Mauad MA, de Souza MP, da Bouzas LFS, Tavares deBarrosChiattonePaz RCBJCRA et al (2015) Survival and graft-versus-host disease in patients receiving peripheral stem cell compared to bone marrow transplantation from HLA-matched related donor: retrospective analysis of 334 consecutive patients. Eur J Haematol 95:421–425
doi: 10.1111/ejh.12508 pubmed: 25645430
Coccia PF, Altman J, Bhatia S, Borinstein SC, Flynn J, George S, Goldsby R, Hayashi R, Huang MS, Johnson RH et al (2012) Adolescent and young adult oncology. Clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN 10:1112–1150
doi: 10.6004/jnccn.2012.0117 pubmed: 22956810
Curran E, Stock W (2015) How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood 125:3702–3710
doi: 10.1182/blood-2014-11-551481 pubmed: 25805810 pmcid: 4463735
de Bont JM, van der Holt B, Dekker AW, van der Does-van den Berg, A., Sonneveld, P., and Pieters, R. (2004) Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 18:2032–2035
doi: 10.1038/sj.leu.2403538 pubmed: 15483674
Dini G, Zecca M, Balduzzi A, Messina C, Masetti R, Fagioli F, Favre C, Rabusin M, Porta F, Biral E et al (2011) No difference in outcome between children and adolescents transplanted for acute lymphoblastic leukemia in second remission. Blood 118:6683–6690
doi: 10.1182/blood-2011-05-354233 pubmed: 22010101
Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR, Ringdén O, Wagner JE (2004) Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. J Clin Oncol off J Am Soc Clin Oncol 22:4872–4880
doi: 10.1200/JCO.2004.02.189
Giebel S, Labopin M, Socié G, Beelen D, Browne P, Volin L, Kyrcz-Krzemien S, Yakoub-Agha I, Aljurf M, Wu D et al (2017) Improving results of allogeneic hematopoietic cell transplantation for adults with acute lymphoblastic leukemia in first complete remission: an analysis from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 102:139–149
doi: 10.3324/haematol.2016.145631 pubmed: 27686376 pmcid: 5210244
Goldstone AH, Richards SM, Lazarus HM, Tallman MS, Buck G, Fielding AK, Burnett AK, Chopra R, Wiernik PH, Foroni L et al (2008) In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 111:1827–1833
doi: 10.1182/blood-2007-10-116582 pubmed: 18048644
Hangai M, Urayama KY, Tanaka J, Kato K, Nishiwaki S, Koh K, Noguchi M, Kato K, Yoshida N, Sato M et al (2019) Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adolescents and young adults. Biol Blood Marrow Transplant 25:1597–1602
doi: 10.1016/j.bbmt.2019.04.014 pubmed: 31002992
Iacobucci I, Mullighan CG (2017) Genetic basis of acute lymphoblastic leukemia. J Clin Oncol off J Am Soc Clin Oncol 35:975–983
doi: 10.1200/JCO.2016.70.7836
Ibrahim A, Ali A, Mohammed MM (2014) Outcome of adolescents with acute lymphoblastic leukemia treated by pediatrics versus adults protocols. Adv Hematol 2014:697675
Ma SK, Wan TS, Chan LC (1999) Cytogenetics and molecular genetics of childhood leukemia. Hematol Oncol 17:91–105
doi: 10.1002/(SICI)1099-1069(199909)17:3<91::AID-HON643>3.0.CO;2-Y pubmed: 10641030
Majhail NS, Brazauskas R, Hassebroek A, Bredeson CN, Hahn T, Hale GA, Horowitz MM, Lazarus HM, Maziarz RT, Wood WA et al (2012) Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 18:861–873
doi: 10.1016/j.bbmt.2011.10.031
Martin PJ, Weisdorf D, Przepiorka D, Hirschfeld S, Farrell A, Rizzo JD, Foley R, Socie G, Carter S, Couriel D et al (2006) National Institutes of health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: VI. Design of Clinical Trials Working Group report. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 12:491–505
doi: 10.1016/j.bbmt.2006.03.004
McGrady ME, Williams SN, Davies SM, Pai ALH (2014) Adherence to outpatient oral medication regimens in adolescent hematopoietic stem cell transplant recipients. Eur J Oncol Nurs off J Eur Oncol Nurs Soc 18:140–144
doi: 10.1016/j.ejon.2013.11.007
Mehta PA, Rotz SJ, Majhail NS (2018) Unique challenges of hematopoietic cell transplantation in adolescent and young adults with hematologic malignancies. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 24:e11–e19
doi: 10.1016/j.bbmt.2018.09.011
Peters C, Schrappe M, von Stackelberg A, Schrauder A, Bader P, Ebell W, Lang P, Sykora K-W, Schrum J, Kremens B et al (2015) Stem-cell transplantation in children with acute lymphoblastic leukemia: a prospective international multicenter trial comparing sibling donors with matched unrelated donors—the ALL-SCT-BFM-2003 Trial. J Clin Oncol 33:1265–1274
doi: 10.1200/JCO.2014.58.9747 pubmed: 25753432
Peters C, Dalle J-H, Locatelli F, Poetschger U, Sedlacek P, Buechner J, Shaw PJ, Staciuk R, Ifversen M, Pichler H, et al (2020) Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study. J Clin Oncol 39(4):295–307
Pochon C, Detrait M, Dalle J-H, Michel G, Dhédin N, Chalandon Y, Brissot E, Forcade E, Sirvent A, Izzadifar-Legrand F, et al (2021) Improved outcome in children compared to adolescents and young adults after allogeneic hematopoietic stem cell transplant for acute myeloid leukemia: a retrospective study from the Francophone Society of Bone Marrow Transplantation and Cell Therapy (SFGM-TC). J Cancer Res Clin Oncol online ahead of print
Pui C-H, Pei D, Campana D, Bowman WP, Sandlund JT, Kaste SC, Ribeiro RC, Rubnitz JE, Coustan-Smith E, Jeha S et al (2011) Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 29:386–391
doi: 10.1200/JCO.2010.32.0325 pubmed: 21172890
Pulewka K, Strauss B, Hochhaus A, Hilgendorf I (2020) Clinical, social, and psycho-oncological needs of adolescents and young adults (AYA) versus older patients following hematopoietic stem cell transplantation. J Cancer Res Clin Oncol 147(4):1239–1246
Rank CU, Schmiegelow K (2020) Optimal approach to the treatment of young adults with acute lymphoblastic leukemia in 2020. Semin Hematol 57:102–114
doi: 10.1053/j.seminhematol.2020.08.001 pubmed: 33256899
Shago M (2017) Recurrent cytogenetic abnormalities in acute lymphoblastic leukemia. Methods Mol Biol Clifton NJ 1541:257–278
doi: 10.1007/978-1-4939-6703-2_21
Singh AK, McGuirk JP (2016) allogeneic stem cell transplantation: a historical and scientific overview. Cancer Res 76:6445–6451
doi: 10.1158/0008-5472.CAN-16-1311 pubmed: 27784742
Soulier J, Trakhtenbrot L, Najfeld V, Lipton JM, Mathew S, Avet-Loiseau H, De Braekeleer M, Salem S, Baruchel A, Raimondi SC et al (2003) Amplification of band q22 of chromosome 21, including AML1, in older children with acute lymphoblastic leukemia: an emerging molecular cytogenetic subgroup. Leukemia 17:1679–1682
doi: 10.1038/sj.leu.2403000 pubmed: 12886264
Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, Larson RA, Nachman J, Children’s Cancer Group, and Cancer and Leukemia Group B studies (2008) What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood 112:1646–1654
doi: 10.1182/blood-2008-01-130237 pubmed: 18502832 pmcid: 2518876
Stock W, Douer D, DeAngelo DJ, Arellano M, Advani A, Damon L, Kovacsovics T, Litzow M, Rytting M, Borthakur G et al (2011) Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 52:2237–2253
doi: 10.3109/10428194.2011.596963 pubmed: 21827361
Tewari P, Franklin AR, Tarek N, Askins MA, Mofield S, Kebriaei P (2014) Hematopoietic stem cell transplantation in adolescents and young adults. Acta Haematol 132:313–325
doi: 10.1159/000360211 pubmed: 25228557
Toft N, Birgens H, Abrahamsson J, Griškevičius L, Hallböök H, Heyman M, Klausen TW, Jónsson ÓG, Palk K, Pruunsild K et al (2018) Results of NOPHO ALL2008 treatment for patients aged 1–45 years with acute lymphoblastic leukemia. Leukemia 32:606–615
doi: 10.1038/leu.2017.265 pubmed: 28819280
Trama A, Botta L, Foschi R, Ferrari A, Stiller C, Desandes E, Maule MM, Merletti F, Gatta G, EUROCARE-5 Working Group (2016) Survival of European adolescents and young adults diagnosed with cancer in 2000–07: population-based data from EUROCARE-5. Lancet Oncol 17:896–906
doi: 10.1016/S1470-2045(16)00162-5 pubmed: 27237614
Wood W, Deal A, Whitley J, Sharf A, Serody J, Gabriel D, Shea T (2011) Usefulness of the hematopoietic cell transplantation-specific comorbidity index (HCT-CI) in predicting outcomes for adolescents and young adults with hematologic malignancies undergoing allogeneic stem cell transplant. Pediatr Blood Cancer 57:499–505
doi: 10.1002/pbc.23057 pubmed: 21384538
Wood WA, Lee SJ, Brazauskas R, Wang Z, Aljurf MD, Ballen KK, Buchbinder DK, Dehn J, Freytes CO, Lazarus HM et al (2014) Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia. Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant 20:829–836
doi: 10.1016/j.bbmt.2014.02.021
Zheng C, Zhu X, Tang B, Yao W, Song K, Tong J, Geng L, Liu H, Sun Z (2015) Comparative analysis of unrelated cord blood transplantation and HLA-matched sibling hematopoietic stem cell transplantation in children with high-risk or advanced acute leukemia. Ann Hematol 94:473–480
doi: 10.1007/s00277-014-2213-y pubmed: 25217231

Auteurs

Audrey Grain (A)

Pediatric Hematology-Oncology Department, CHU Hopital Mère-Enfant, Nantes, France. audrey.grain.chu@gmail.com.

Fanny Rialland-Battisti (F)

Pediatric Hematology-Oncology Department, CHU Hopital Mère-Enfant, Nantes, France.

Patrice Chevallier (P)

Hematology Department, CHU Hotel Dieu, Nantes, France.

Nicolas Blin (N)

Hematology Department, CHU Hotel Dieu, Nantes, France.

Jean-Hugues Dalle (JH)

Robert Debré University Hospital (APHP), Université de Paris, Paris, France.

Gérard Michel (G)

Department of Paediatric Haematology and Oncology and EA3279, Timone Children Hospital and Aix-Marseille University, Marseille, France.

Nathalie Dhédin (N)

AYA Unit, Clinical Hematology Departments, Saint-Louis Hospital, Paris, France.

Regis Peffault de Latour (R)

BMT Unit, Department of Hematology, Hospital St. Louis, Paris, France.

Cécile Pochon (C)

Allogeneic Hematopoietic Stem Cell Transplantation Unit, Department of Pediatric Oncohematology, Nancy University Hospital, Vandœuvre-lès-Nancy, France.

Ibrahim Yakoub-Agha (I)

CHU de Lille, Université de Lille, LIRIC, Inserm U995, Lille, France.

Yves Bertrand (Y)

Institut of Hematology and Pediatric Oncology, Hospices Civils de Lyon, Université Lyon 1, Lyon, France.

Anne Sirvent (A)

Department of Clinical Haematology, CHU Montpellier, Montpellier, France.

Charlotte Jubert (C)

Department of Pediatric Hematology, Bordeaux Hospital, Bordeaux, France.

Edouard Forcade (E)

Department of Hematology and Cellular Therapy, CHU Bordeaux, Bordeaux, France.

Ana Berceanu (A)

Department of Hematology, CHU Besançon, Besançon, France.

Virginie Gandemer (V)

Department of Pediatric Oncology and Haematology, University Hospital of Rennes, Rennes, France.

Pascale Schneider (P)

Department of Pediatric Hematology and Oncology, Centre Hospitalo-Universitaire de Rouen, Rouen, France.

Jacques-Olivier Bay (JO)

Department of Hematology and Cellular Therapy CHU Estaing, CHU Clermont-Ferrand, Clermont-Ferrand, France.

Pierre-Simon Rohrlich (PS)

Pediatric Hematology Department, CHU de Nice, Nice, France.

Eolia Brissot (E)

Department of Haematology, Hôpital Saint-Antoine, Paris, France.

Catherine Paillard (C)

Pediatric Oncohematology and Bone Marrow Transplantation Unit, Hôpital de Hautepierre, CHRU, Strasbourg, France.

Dominique Plantaz (D)

Department of Pediatric Hematology-Oncology, University Hospital Grenoble, Grenoble, France.

Stéphanie Nguyen Quoc (S)

Department of Hematology, La Pitié University Hospital, Paris, France.

Fanny Gonzales (F)

Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277, CANTHER, Cancer Heterogeneity Plasticity and Resistance to Therapies, 59000, Lille, France.

Natacha Maillard (N)

Hematology Department, CHU Poitiers, Poitier, France.

Lucie Planche (L)

Clinical Research Unit, CHD Vendée, La Roche sur Yon, France.

André Baruchel (A)

Robert Debré University Hospital (APHP), Université de Paris, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH